Induction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestations

Journal of Neuroimmunology

Volumn 232, Issue 1-2, 2011, Pages 151-157

  Telerman, Alona ^a   Lapter, Smadar ^a   Sharabi, Amir ^a   Zinger, Heidy ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

A model of systemic lupus erythematosus; A tolerogenic peptide; ERK and Akt pathways; Growth and neurotrophic factors; Hippocampal neurogenesis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BROXURIDINE; HCDR1 PEPTIDE; IMMUNOMODULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NEURON SPECIFIC NUCLEAR PROTEIN; PROTEIN KINASE B; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFECT; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; IMMUNOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MICE; NERVE GROWTH FACTORS; NEUROGENESIS; PEPTIDE FRAGMENTS; PROTEIN KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 79952248042     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.11.001     Document Type: Article

References (51)

1. Aberg M.A., Aberg N.D., Hedbacker H., Oscarsson J., Eriksson P.S. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J. Neurosci. 2000, 20:2896-2903.
2. Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 2005, 25:8217-8228.
3. Aharoni R., Eilam R., Domev H., Labunskay G., Sela M., Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl Acad. Sci. USA 2005, 102:19045-19050.
4. Appenzeller S., Carnevalle A.D., Li L.M., Costallat L.T., Cendes F. Hippocampal atrophy in systemic lupus erythematosus. Ann. Rheum. Dis. 2006, 65:1585-1589.
5. Ballok D.A. Neuroimmunopathology in a murine model of neuropsychiatric lupus. Brain Res. Rev. 2007, 54:67-79.
6. Balu D.T., Lucki I. Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology. Neurosci. Biobehav. Rev. 2009, 33:232-252.
7. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
8. Calof A.L. Intrinsic and extrinsic factors regulating vertebrate neurogenesis. Curr. Opin. Neurobiol. 1995, 5:19-27.
9. Cameron H.A., Gould E. Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience 1994, 61:203-209.
10. Chen J., Zhang Z.G., Li Y., Wang Y., Wang L., Jiang H., Zhang C., Lu M., Katakowski M., Feldkamp C.S., Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann. Neurol. 2003, 53:743-751.
11. Crupi R., Cambiaghi M., Spatz L., Hen R., Thorn M., Friedman E., Vita G., Battaglia F. Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice. Biol. Psychiatry 2010, 67:558-566.
12. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13:2905-2927.
13. Daw M.I., Bortolotto Z.A., Saulle E., Zaman S., Collingridge G.L., Isaac J.T. Phosphatidylinositol 3 kinase regulates synapse specificity of hippocampal long-term depression. Nat. Neurosci. 2002, 5:835-836.
14. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001, 7:1189-1193.
15. Duman C.H., Schlesinger L., Kodama M., Russell D.S., Duman R.S. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol. Psychiatry 2007, 61:661-670.
16. Frielingsdorf H., Simpson D.R., Thal L.J., Pizzo D.P. Nerve growth factor promotes survival of new neurons in the adult hippocampus. Neurobiol. Dis. 2007, 26:47-55.
17. Gould E., Cameron H.A., Daniels D.C., Woolley C.S., McEwen B.S. Adrenal hormones suppress cell division in the adult rat dentate gyrus. J. Neurosci. 1992, 12:3642-3650.
18. Hahn B.H. An overview of the pathogenesis of systemic lupus erythematosus. Dubois' Lupus Erythematosus 2006, 46-53. Lippincott Williams & Wilkins, Philadelphia, PA. 4th ed. D.J. Wallace, B.H. Hahn (Eds.).
19. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., Gould T.D., Manji H.K., Chen G. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 2004, 24:6590-6599.
20. Hetman M., Kanning K., Cavanaugh J.E., Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J. Biol. Chem. 1999, 274:22569-22580.
21. Johnson-Farley N.N., Patel K., Kim D., Cowen D.S. Interaction of FGF-2 with IGF-1 and BDNF in stimulating Akt, ERK, and neuronal survival in hippocampal cultures. Brain Res. 2007, 1154:40-49.
22. Katzav A., Solodeev I., Brodsky O., Chapman J., Pick C.G., Blank M., Zhang W., Reichlin M., Shoenfeld Y. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum. 2007, 56:938-948.
23. Kuhn H.G., Winkler J., Kempermann G., Thal L.J., Gage F.H. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J. Neurosci. 1997, 17:5820-5829.
24. Lapter S., Marom A., Meshorer A., Elmann A., Sharabi A., Vadai E., Neufeld A., Sztainberg Y., Gil S., Getselter D., Chen A., Mozes E. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide. Arthritis Rheum. 2009, 60:3744-3754.
25. Lessmann V., Gottmann K., Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 2003, 69:341-374.
26. Leuner B., Mendolia-Loffredo S., Kozorovitskiy Y., Samburg D., Gould E., Shors T.J. Learning enhances the survival of new neurons beyond the time when the hippocampus is required for memory. J. Neurosci. 2004, 24:7477-7481.
27. Luger D., Dayan M., Zinger H., Liu J.P., Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol. 2004, 24:579-590.
28. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., Tschopp J., Browning J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 1999, 190:1697-1710.
29. Mackay F., Sierro F., Grey S.T., Gordon T.P. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 2005, 8:243-265.
30. Molnár I., Bokk A. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases. Cytokine 2006, 35:109-114.
31. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
32. Nagy G., Koncz A., Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit. Rev. Immunol. 2005, 25:123-140.
33. Parameswaran R., Ben David H., Sharabi A., Zinger H., Mozes E. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin. Immunol. 2009, 131:223-232.
34. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
35. Rapoport M.J., Sharabi A., Aharoni D., Bloch O., Zinger H., Dayan M., Mozes E. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin. Immunol. 2005, 117:262-270.
36. Sakic B., Kirkham D.L., Ballok D.A., Mwanjewe J., Fearon I.M., Macri J., Guanhua Y., Sidor M.M., Denburg J.A., Szechtman H., Lau J., Ball A.K., Doering L.C. Proliferating brain cells are a target of neurotoxic CSF in systemic autoimmune disease. J. Neuroimmunol. 2005, 169:68-85.
37. Sela U., Dayan M., Hershkoviz R., Cahalon L., Lider O., Mozes E. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur. J. Immunol. 2006, 36:2971-2980.
38. Sela U., Sharabi A., Dayan M., Hershkoviz R., Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology 2009, 128:e395-e405.
39. Sharabi A., Mozes E. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. J. Immunol. 2008, 181:3243-3251.
40. Sharabi A., Zinger H., Zborowsky M., Sthoeger Z.M., Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+ CD25+ cells and TGF-beta. Proc. Natl Acad. Sci. USA 2006, 103:8810-8815.
41. Sharabi A., Luger D., Ben-David H., Dayan M., Zinger H., Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J. Immunol. 2007, 179:4979-4987.
42. Stanojcic M., Burstyn-Cohen T., Nashi N., Lemke G., Sakic B. Disturbed distribution of proliferative brain cells during lupus-like disease. Brain Behav. Immun. 2009, 23:1003-1013.
43. Sthoeger Z.M., Dayan M., Tcherniack A., Green L., Toledo S., Segal R., Elkayam O., Mozes E. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin. Exp. Immunol. 2003, 131:385-392.
44. Sung S.M., Jung D.S., Kwon C.H., Park J.Y., Kang S.K., Kim Y.K. Hypoxia/reoxygenation stimulates proliferation through PKC-dependent activation of ERK and Akt in mouse neural progenitor cells. Neurochem. Res. 2007, 32:1932-1939.
45. Tin S.K., Xu Q., Thumboo J., Lee L.Y., Tse C., Fong K.Y. Novel brain reactive autoantibodies: prevalence in systemic lupus erythematosus and association with psychoses and seizures. J. Neuroimmunol. 2005, 169:153-160.
46. Tomita M., Khan R.L., Blehm B.H., Santoro T.J. The potential pathogenetic link between peripheral immune activation and the central innate immune response in neuropsychiatric systemic lupus erythematosus. Med. Hypotheses 2004, 62:325-335.
47. Turnbull A.V., Rivier C.L. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol. Rev. 1999, 79:1-71.
48. Vallières L., Campbell I.L., Gage F.H., Sawchenko P.E. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J. Neurosci. 2002, 22:486-492.
49. van Dam A.P. Diagnosis and pathogenesis of CNS lupus. Rheumatol. Int. 1991, 11:1-11.
50. Waisman A., Shoenfeld Y., Blank M., Ruiz P.J., Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int. Immunol. 1995, 7:689-696.
51. Zandman-Goddard G., Chapman J., Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin. Arthritis Rheum. 2007, 36:297-315.